These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16902814)

  • 1. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats.
    Dahan A; Hoffman A
    Pharm Res; 2006 Sep; 23(9):2165-74. PubMed ID: 16902814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats.
    Dahan A; Hoffman A
    Eur J Pharm Biopharm; 2007 Aug; 67(1):96-105. PubMed ID: 17329087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation.
    Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y
    Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220.
    Gershkovich P; Qadri B; Yacovan A; Amselem S; Hoffman A
    Eur J Pharm Sci; 2007 Aug; 31(5):298-305. PubMed ID: 17560096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
    Porter CJ; Kaukonen AM; Taillardat-Bertschinger A; Boyd BJ; O'Connor JM; Edwards GA; Charman WN
    J Pharm Sci; 2004 May; 93(5):1110-21. PubMed ID: 15067688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs.
    Dahan A; Hoffman A
    Eur J Pharm Sci; 2005 Mar; 24(4):381-8. PubMed ID: 15734305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach.
    Lee JB; Kim TH; Feng W; Choi HG; Zgair A; Shin S; Yoo SD; Gershkovich P; Shin BS
    J Pharm Sci; 2019 Feb; 108(2):1047-1052. PubMed ID: 30268807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
    White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
    Hauss DJ; Fogal SE; Ficorilli JV; Price CA; Roy T; Jayaraj AA; Keirns JJ
    J Pharm Sci; 1998 Feb; 87(2):164-9. PubMed ID: 9519148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs.
    Holm R; Jørgensen EB; Harborg M; Larsen R; Holm P; Müllertz A; Jacobsen J
    Eur J Pharm Sci; 2011 Mar; 42(4):416-22. PubMed ID: 21256961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80.
    Lind ML; Jacobsen J; Holm R; Müllertz A
    Eur J Pharm Sci; 2008 Oct; 35(3):211-8. PubMed ID: 18675904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration.
    Dahan A; Duvdevani R; Shapiro I; Elmann A; Finkelstein E; Hoffman A
    J Control Release; 2008 Feb; 126(1):1-9. PubMed ID: 18082281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623).
    Trevaskis NL; McEvoy CL; McIntosh MP; Edwards GA; Shanker RM; Charman WN; Porter CJ
    Pharm Res; 2010 May; 27(5):878-93. PubMed ID: 20221896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability.
    Gershkovich P; Hoffman A
    Eur J Pharm Sci; 2005 Dec; 26(5):394-404. PubMed ID: 16140514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
    Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
    Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug.
    Lee KW; Porter CJ; Boyd BJ
    J Pharm Sci; 2013 Feb; 102(2):565-78. PubMed ID: 23242691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems.
    Heshmati N; Cheng X; Dapat E; Sassene P; Eisenbrand G; Fricker G; Müllertz A
    J Pharm Pharmacol; 2014 Nov; 66(11):1567-75. PubMed ID: 24961657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin-loaded lipid nanocarrier for improving bioavailability, stability and cytotoxicity against malignant glioma cells.
    Kumar A; Ahuja A; Ali J; Baboota S
    Drug Deliv; 2016; 23(1):214-29. PubMed ID: 24825490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats.
    Lee KW; Porter CJ; Boyd BJ
    J Pharm Sci; 2013 Nov; 102(11):3957-65. PubMed ID: 23983139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.